Draft:CellxLife
 | This article may incorporate text from a large language model, which is prohibited in Wikipedia articles. (July 2026) |
This draft reads like an advertisement. Wikipedia is an encyclopedia, not a platform for promotion or marketing. Drafts that are exclusively promotional may be deleted without notice.
Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: As a paid editor, you should have a way better understanding of WP:NPOV and WP:NCORP. This is a very low effort submission. Also, using AI to help you create this article when you are being paid to write it yourself is wild. Sulfurboy (talk) 01:57, 31 July 2026 (UTC)
| Type | Private company |
|---|---|
| Industry | Biotechnology |
| Founded | 2023 |
| Founder | Ruvin Orbach |
Key people | Ruvin Orbach (Founder) Eric von Hofe |
| Products | Cancer immunotherapies Therapeutic cancer vaccines |
| Website | www |
CellxLife is a private American biotechnology company headquartered in Los Angeles, California. The company develops cellular immunotherapies and therapeutic cancer vaccines, with research centered on dendritic cell–based immunotherapy platforms and cancer vaccine technologies.
Founded by entrepreneur and healthcare executive Ruvin Orbach, the company focuses on the development and commercialization of immunotherapy technologies intended for multiple forms of cancer. The company's scientific programs are led by oncology researcher and biotechnology executive Dr. Eric von Hofe.
History
[edit]CellxLife was founded by entrepreneur and healthcare executive Ruvin Orbach to advance the development and commercialization of cellular immunotherapies and therapeutic cancer vaccines. Prior to establishing the company, Orbach worked in healthcare investment, commercialization strategy, and biotechnology ventures focused on emerging healthcare technologies.[1]
The company's research and development efforts have focused on immune-based approaches designed to stimulate the body's immune system to recognize and respond to cancer. Its programs include dendritic cell–based immunotherapies and therapeutic cancer vaccine technologies being investigated for multiple forms of cancer.[2]
In 2026, CellxLife expanded its oncology portfolio through the licensing of dendritic cell vaccine technology targeting Folate receptor alpha (FRα), a protein overexpressed in several solid tumor types. The licensed technology had previously entered Phase II clinical studies for ovarian cancer, and CellxLife announced plans to further evaluate the platform for additional FRα-expressing cancers.[3]
The company's development activities have also included cellular immunotherapy programs for Osteosarcoma and Ewing sarcoma, reflecting its broader research into immune-based treatment approaches for cancers with limited therapeutic options.[4]
Technology
[edit]CellxLife's research focuses on the development of cellular immunotherapies and therapeutic cancer vaccines designed to stimulate immune responses against cancer cells. The company's technology portfolio includes Dendritic cell–based immunotherapy platforms intended to activate T cells capable of recognizing tumor-associated antigens.[2]
The company's research has included therapeutic approaches targeting Folate receptor alpha (FRα), a protein that is overexpressed in several types of solid tumors, including ovarian cancer. Dendritic cell vaccines are designed to present tumor-associated antigens to the immune system in an effort to stimulate antigen-specific T-cell responses.[3]
CellxLife's development activities have also included research into immune memory, with therapeutic strategies intended to promote long-term recognition of cancer-associated antigens following treatment. Research has focused on immune-based therapeutic approaches that remain under clinical investigation.[2]
Clinical Programs
[edit]CellxLife's clinical development activities have focused on cellular immunotherapies and therapeutic cancer vaccines for solid tumors and rare cancers. The company's research portfolio includes programs involving pediatric bone cancers as well as therapeutic vaccine technologies targeting tumor-associated antigens.[2]
Osteosarcoma
[edit]CellxLife has been involved in the development of dendritic cell–based immunotherapy for Osteosarcoma, an aggressive form of bone cancer that primarily affects children and adolescents. The therapeutic approach is intended to stimulate immune responses against tumor-associated antigens following standard treatment.[4]
Ewing sarcoma
[edit]The company's research has also included immunotherapy programs for Ewing sarcoma, a rare cancer affecting bone and soft tissue. Development efforts have focused on cellular immunotherapy approaches designed to enhance antigen-specific immune responses.[4]
FRα therapeutic cancer vaccine
[edit]CellxLife has expanded its oncology portfolio through the development of therapeutic vaccine technology targeting folate receptor alpha (FRα), a protein expressed in several solid tumor types. The program is based on dendritic cell vaccine technology that has previously entered Phase II clinical evaluation for Ovarian cancer and is intended for further investigation in additional FRα-expressing cancers.[3][2]
Leadership
[edit]Ruvin Orbach is the founder of CellxLife. Prior to establishing the company, he worked in healthcare investment, commercialization strategy, and biotechnology ventures, focusing on the development and financing of emerging healthcare technologies.[5][6]
The company's scientific programs are led by Dr. Eric von Hofe, an oncology researcher and biotechnology executive whose work has focused on cancer immunotherapy, therapeutic cancer vaccines, and translational oncology research. [6][7]
Together, CellxLife's executive and scientific leadership oversee the company's research, clinical development activities, strategic partnerships, and commercialization initiatives.[6]
See also
[edit]References
[edit]- ^ "CellxLife". CellxLife. Retrieved 2 July 2026.
- ^ a b c d e Foster, Bree (2026-07-01). "Reengineering cancer vaccines for durable immune memory". Drug Discovery News. Retrieved 2026-07-07.
- ^ a b c Mirasol, Feliza (2026-06-17). "CellxLife Licenses Mayo Clinic FRα-Targeting Dendritic Cell Vaccine for Ovarian Cancer". BioPharm International. Retrieved 2026-07-07.
- ^ a b c Maia, Margarida (2026-06-17). "CellxLife gains license to ovarian cancer vaccine in clinical trials". Rare Cancer News. Retrieved 2026-07-07.
- ^ "Founder". CellxLife. Retrieved 2026-07-07.
- ^ a b c Napitupulu, Jon (2026-06-18). "Unveiling the Remarkable Team Driving a Revolutionary Pediatric Cancer Vaccine". Clinical Trial Vanguard. Retrieved 2026-07-07.
- ^ "Scientific Leadership". CellxLife. Retrieved 2026-07-07.
- provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.